ZA967880B - Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha - Google Patents

Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha

Info

Publication number
ZA967880B
ZA967880B ZA967880A ZA967880A ZA967880B ZA 967880 B ZA967880 B ZA 967880B ZA 967880 A ZA967880 A ZA 967880A ZA 967880 A ZA967880 A ZA 967880A ZA 967880 B ZA967880 B ZA 967880B
Authority
ZA
South Africa
Prior art keywords
inhibition
tumor necrosis
patho
mammals
alpha
Prior art date
Application number
ZA967880A
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Publication of ZA967880B publication Critical patent/ZA967880B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA967880A 1995-09-19 1996-09-18 Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha ZA967880B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US395595P 1995-09-19 1995-09-19

Publications (1)

Publication Number Publication Date
ZA967880B true ZA967880B (en) 1997-04-16

Family

ID=21708393

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA967880A ZA967880B (en) 1995-09-19 1996-09-18 Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha

Country Status (11)

Country Link
EP (1) EP0866656B1 (xx)
JP (1) JPH11512699A (xx)
AT (1) ATE360419T1 (xx)
AU (1) AU709178B2 (xx)
BR (1) BR9610480A (xx)
CA (1) CA2232191C (xx)
DE (2) DE69637050T2 (xx)
MX (1) MX9802150A (xx)
TW (1) TW449473B (xx)
WO (1) WO1997010712A1 (xx)
ZA (1) ZA967880B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
ES2221365T3 (es) * 1998-03-17 2004-12-16 Solomon B. Margolin Composiciones y metodos topicos antisepticos.
US6548550B1 (en) * 1999-08-06 2003-04-15 Innovet Italia S.R.L. Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field
AU2001230605A1 (en) * 2000-02-09 2001-08-20 Shionogi And Co., Ltd. Apoptosis inhibitor
AU2001278699A1 (en) * 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서함유하는 의약 제제
BR0307631A (pt) * 2002-02-14 2004-12-21 Pharmacia Corp Piridinonas substituìdas como moduladores de p38 map-quinase
AU2007202607B2 (en) * 2002-02-14 2008-12-18 Pharmacia Corporation Substituted Pyridinones as Modulators of p38 MAP Kinase
KR100901931B1 (ko) 2002-02-14 2009-06-10 파마시아 코포레이션 Ｐ３８ ｍａｐ 키나제의 조절제로서의 치환된 피리디논
EP2987788A1 (en) * 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
SG153727A1 (en) * 2003-02-14 2009-07-29 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
NL1026826C2 (nl) * 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
CA2545813C (en) * 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
ES2600460T3 (es) * 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP2029572B1 (en) * 2006-06-05 2010-11-03 Novartis AG Organic compounds
ES2567283T3 (es) 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
CN111991393A (zh) * 2019-09-26 2020-11-27 深圳先进技术研究院 吡非尼酮在制备防治类风湿性关节炎的药物中的应用
IL297296A (en) * 2020-04-14 2022-12-01 Excalibur Pharmaceuticals Inc Pirfenidone for the treatment of the corona virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5227399A (en) * 1991-02-28 1993-07-13 Merck Frosst Canada, Inc. Pyranylphenyl naphthalene lactones as inhibitors of leukotriene biosynthesis
WO1993007141A1 (en) * 1991-10-11 1993-04-15 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
DE69632396T2 (de) * 1995-03-03 2005-05-04 Margolin, Solomon B., Dallas Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden

Also Published As

Publication number Publication date
WO1997010712A1 (en) 1997-03-27
EP0866656B1 (en) 2007-04-25
EP0866656A1 (en) 1998-09-30
TW449473B (en) 2001-08-11
ATE360419T1 (de) 2007-05-15
CA2232191C (en) 2011-03-15
EP0866656A4 (en) 2001-05-23
JPH11512699A (ja) 1999-11-02
MX9802150A (es) 1998-11-30
BR9610480A (pt) 1999-03-16
DE122011100032I1 (de) 2012-05-16
DE69637050T2 (de) 2008-06-19
CA2232191A1 (en) 1997-03-27
DE69637050D1 (de) 2007-06-06
AU709178B2 (en) 1999-08-26
AU7239996A (en) 1997-04-09

Similar Documents

Publication Publication Date Title
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
BG104619A (en) Oral pharmaceutical pulsed release dosage form
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
MY115662A (en) Novel compounds with analgesic effect
RS20090086A (xx) Nukleozidni analozi sa karboksamidinski modifikovanim monocikličnim bazama
GEP20002013B (en) Therapeutical Means
MY119403A (en) Novel compounds with analgesic effect.
IL123889A0 (en) Pharmaceutical angiostatic dipeptide compositions and methods of use thereof
WO1994027589A3 (en) Antidepressant dosage form
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ZA965969B (en) Salts derived from amidine and cyclooxygenase inhibitor process for the preparation thereof their application as medicinal drugs and pharmaceutical compositions in which they are contained
ZA966163B (en) Novel galanthamine derivatives, process for the preparation thereof, their application as medical drugs, and pharmaceutical compositions containing said derivatives.
BG101875A (en) New cryptoficins and method for their preparation
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
EP0813409A4 (en) TREATMENT OF DISEASES CAUSED BY THE CYTOKIN GROWTH FACTOR
EP0542860A4 (en) Immunosuppressive compositions
EP0744176A3 (en) Methods for inhibiting bone loss
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.